Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Elotuzumab Triplet Approved in Europe for Multiple Myeloma

Jason M. Broderick @jasoncology
Published: Tuesday, Aug 27, 2019

 Meletios A. Dimopoulos, MD

Meletios A. Dimopoulos, MD
The European Commission has approved elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor (PI).

The approval is based on findings from the phase II ELOQUENT-3 trial, in which the addition of elotuzumab to pomalidomide and dexamethasone reduced the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x